A Phase 2, Open-Label Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation

Trial Profile

A Phase 2, Open-Label Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2016

At a glance

  • Drugs Rucaparib (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms RUCAPANC
  • Sponsors Clovis Oncology
  • Most Recent Events

    • 16 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 07 Jun 2016 Status changed from completed to discontinued as reported by results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2016 According to Clovis Oncology media release, final results of the RUCAPANC study presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top